Efficacy of conventional cytogenetics and FISH for EGR1 to detect deletion 5q in hematological disorders and to assess response to treatment with Lenalidomide

被引:10
作者
Zou, Ying S.
Fink, Stephanie R.
Stockero, Kimberly J.
Paternoster, Sarah F.
Smoley, Stephanie A.
Tun, Han W.
Reeder, Craig B.
Tefferi, Ayalew
Dewald, Gordon W.
机构
[1] Mayo Clin, Div Lab Genet, Rochester, MN 55905 USA
[2] Mayo Clin, Jacksonville, FL 32224 USA
[3] Mayo Clin, Scottsdale, AZ USA
关键词
deletion; 5q; EGR1; myelodysplasia; acute leukemia;
D O I
10.1016/j.leukres.2006.10.011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In clinical practice, whether FISH for EGR1 in interphase nuclei has similar efficacy to detect deletion 5q anomalies as conventional cytogenetic studies is unknown. We compared conventional cytogenetics and FISH for 145 patients with deletion 5q and detected this anomaly by both methods in 144. Nine patients with myelodysplasia were studied before and after treatment with Lenalidomide and results were concordant for 28 of 29 specimens. FISH did not detect anomalies other than deletion 5q in 31 patients. This study suggests FISH is useful to detect deletion 5q, but is not a substitute for conventional cytogenetics. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1185 / 1189
页数:5
相关论文
共 18 条
[1]   Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution [J].
Bernasconi, P ;
Klersy, C ;
Boni, M ;
Cavigliano, PM ;
Calatroni, S ;
Giardini, I ;
Rocca, B ;
Zappatore, R ;
Caresana, M ;
Quarna, J ;
Lazzarino, M ;
Bernasconi, C .
LEUKEMIA, 2005, 19 (08) :1424-1431
[2]  
Bigoni R, 2001, HAEMATOLOGICA, V86, P375
[3]  
DEWALD GW, 1985, BLOOD, V66, P189
[4]  
DEWALD GW, 2005, HEMATOLOGY BASIC PRI, V53, P928
[5]   Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies [J].
Giagounidis, AAN ;
Germing, U ;
Aul, C .
CLINICAL CANCER RESEARCH, 2006, 12 (01) :5-10
[6]   Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup [J].
Giagounidis, AAN ;
Germing, U ;
Strupp, C ;
Hildebrandt, B ;
Heinsch, M ;
Aul, C .
ANNALS OF HEMATOLOGY, 2005, 84 (09) :569-571
[7]   Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31 [J].
Giagounidis, AAN ;
Germing, U ;
Haase, S ;
Hildebrandt, B ;
Schlegelberger, B ;
Schoch, C ;
Wilkens, L ;
Heinsch, M ;
Willems, H ;
Aivado, M ;
Aul, C .
LEUKEMIA, 2004, 18 (01) :113-119
[8]   Myelodysplasia [J].
Heaney, ML ;
Golde, DV .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (21) :1649-1660
[9]   Polymerase chain reaction-based diagnosis of Del(5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval [J].
Horrigan, SK ;
Westbrook, CA ;
Kim, AH ;
Banerjee, M ;
Stock, W ;
Larson, RA .
BLOOD, 1996, 88 (07) :2665-2670
[10]   Primary myelodysplastic syndrome with normal cytogenetics: utility of 'FISH panel testing' and M-FISH [J].
Ketterling, RP ;
Wyatt, WA ;
VanWier, SA ;
Law, M ;
Hodnefield, JM ;
Hanson, CA ;
Dewald, GW .
LEUKEMIA RESEARCH, 2002, 26 (03) :235-240